Trial Profile

Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fingolimod (Primary)
Indications Cardiovascular disorders
Focus Adverse reactions
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

20 Oct 2020 Status changed from recruiting to completed.
05 Mar 2020 This trial has been completed in Belgium, according to the European Clinical Trials Database.
16 Apr 2015 Planned number of patients changed from 200 to 40, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com